Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

MorphoSys AG. (8/3/17). "Press Relase: MorphoSys Reports Significant Progress in Its Therapeutic Programs in Second Quarter of 2017". Planegg.

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
  Organisation 2 Janssen Biotech Inc. (JBI)
  Group Johnson & Johnson (JnJ) (Group)
Products Product Tremfya™
  Product 2 MOR208 (MorphoSys/Xencor, formerly XmAb5574)
Persons Person Moroney, Simon E. (MorphoSys 1992– CEO + Founder)
  Person 2 Linnartz, Anke (MorphoSys 201611– Head Corp Communications + IR before Gerresheimer + Demag Cranrd + GEA + MIS)
     


   
Record changed: 2017-08-10

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top